NEOGEN CORP NEOG
NEOGEN CORP (NEOG) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $870.4M at a -0.9% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.63 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.117 |
| Retained earnings / assets | -0.156 |
| EBIT / assets | -0.308 |
| Equity / liabilities | 1.509 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| NEOG | NEOGEN CORP | 4/9 | -0.23 | — | -2.7% |
| MYGN | MYRIAD GENETICS INC | 5/9 | -5.88 | — | -1.6% |
| LNTH | Lantheus Holdings, Inc. | 4/9 | 4.61 | 30.6 | +0.5% |
| NTLA | Intellia Therapeutics, Inc. | 2/9 | -6.12 | — | +16.9% |
| TKNO | Alpha Teknova, Inc. | 5/9 | -1.59 | — | +7.4% |
| ICCC | IMMUCELL CORP /DE/ | 6/9 | 2.93 | — | +4.3% |
| NNNN | Anbio Biotechnology | 4/9 | — | 326.5 | — |
About NEOGEN CORP
Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and complementary products to detect dangerous and unintended substances in human food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns, as well as food quality and nutritional components. It also provides software systems that help testers analyze and store results; natural toxin tests; rapid sanitation tests; culture and prepared media products; filter tests for microbial analysis of water; sample collection products; and food safety analysis laboratory services. This segment sells its products to the milling and grain, meat and poultry, ready-to-eat, fruits and vegetables, seafood, dairy, beverage, water, healthcare, traditional culture media markets, food service, and dietary supplements markets. Its Animal Safety segment provides reagents and test kits for use in immunoassay production, forensic and animal toxicology, and life science research, as well as colorimetric and chemiluminescent substrates; veterinary instruments and disposables; animal care and other products, including digestive aids and nutritional supplements; rodent and insect control products, and disinfectants; and genomics services, such as DNA genotyping, sequencing, and trait analysis for livestock and companion animals. This segment sells its products to companion animal veterinarians; livestock producers, veterinarians, and breed associations; retailers; breeding and genetics companies; diagnostic labs and universities; distributors; and other manufacturers and government agencies. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.
FAQ
Is NEOG financially healthy?
NEOGEN CORP's Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does NEOG pay a dividend?
No, NEOGEN CORP does not currently pay a dividend.
How profitable is NEOG?
In FY2025, NEOGEN CORP had a net margin of -0.9% and a return on equity of -0.4%.
Is NEOG overvalued or undervalued?
NEOGEN CORP trades at about 50.9× trailing earnings — below its 10-year norm (10-year range 74.1×–161.5×, median 117.2×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for NEOG?
The average Wall-Street price target for NEOGEN CORP is $12.00, about 4.7% above the recent price, from 3 analysts (consensus: buy).
Is NEOG a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on NEOGEN CORP: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-05-31. Facts plus Stocktoria's own computed scores — not investment advice.